Immunicum AB: the nomination Committee proposes Michael Oredsson as new chairman of the board of Immunicum AB (publ)

Press release

14 march 2018

The nomination committee proposes Michael Oredsson as new chairman of the board of Immunicum AB (publ)

The nomination committee has informed the company that for the annual general meeting 2018 proposes Michael Oredsson as new chairman of the board. Current chairman of the board Agneta Edberg has stated that she declined re-election.

“The election committee has deemed that Michael’s broad and successful affärsbakgrund in combination with specific experience and knowledge of the konkurrenslandskapet in immunonkologi are important assets for the company in the future. Michael also has experience of initiating and running collaborations with industrial partners, which is a key activity for the company,” commented chairman Martin Lindström.

“Immunicum has now created a stronger foundation to stand on and is better positioned for the future clinical development. The nomination committee assesses that this development implies a need for a different skills to the board,” continues Lindstrom

Michael Oredsson is an Mba with an international focus, and was until the end of the year CEO of the listed Bioinvent. Before that, Michael was CEO of Probi (2007-2013), Biosignal, in Australia (2002-2007), and Nutripharma in Norway (1999-2001). During the eighties and nineties he worked in senior management positions in companies like Pharmacia, M&M/Mars and Nestlé. Michael is currently chairman of the board of Ectin AB and board member of PULS AB, former styrelseerfarenhet include, among other things, LIDDS AB (chairman), the SP and the EBCRC and the Biosignal in Australia.

The information is such that Immunicum is obliged to publish in accordance with the EU regulation on market abuse. The information was submitted for publication, through the following contact person in the government, on 14 march 2018, at 13.00 CET

For further information, please contact:

Martin Lindstrom, chairman of the Nomination committee

Telephone: +46 (0) 70 368 6515

Carlos de Sousa, CEO, Immunicum

Telephone: +46 (0) 76 243 6810


Press release the nomination committee proposes new ordförande_180314 final

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Immunicum AB via Globenewswire